Bayer

500 articles with Bayer

• Bayer Statement on Jury's Decision in Phase 1 of California Glyphosate Trial

  3/19/2019

  Bayer released the following statement in reaction to a phase one verdict in favor of the plaintiff in the case of Hardeman v Monsanto, a trial conducted in the federal glyphosate multi-district litigation before Judge Vince Chhabria in the Northern District of California.

• Bayer statement on new 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease

  3/17/2019

  No one should start, stop or modify an aspirin regimen without first speaking with their healthcare provider.

• Bayer's Phase III Clinical Trial Of Nifurtimox In Pediatric Patients With Chagas Disease Meets Primary Endpoint

  3/14/2019

  Bayer presented results today from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinical study of investigational nifurtimox in pediatric patients with Chagas disease at the "XV Taller sobre la enfermedad de Chagas" conference in Barcelona, Spain.

• The Climate Corporation and NAU Country Insurance Company Partner to Enable Seamless Crop Insurance Reporting for U.S. Farmers

  3/5/2019

  The Climate Corporation, a subsidiary of Bayer, announced a platform agreement between the company's industry-leading Climate FieldView™ digital agriculture platform and NAU Country Insurance Company, a QBE Insurance Company.

• Evotec Receives Milestone Payment For Start Of Second Phase Ii Trial In Its Multi-target Alliance With Bayer

  2/28/2019

  Evotec AG announced that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough.

• 

  Second Lawsuit Alleging Bayer’s Roundup Led to the Development of Cancer Begins

  2/28/2019

  Could a product in a weed killer contribute to the development of a cancer? That is the question a jury will answer as Bayer faces accusations that glyphosate, the active ingredient in its top=selling weed killer Roundup, caused cancer in some individuals who have used the product.
• 

  BioSpace's Global Biopharma Roundup: Feb. 28

  2/28/2019

  BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.

• Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)

  2/27/2019

  Bayer announced the completion of the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational drug darolutamide.

• "Wall Smashing" Ceremony Initiates Construction Of Bayer Funded Geospatial Innovation And Resource Center at T-REX Business Incubator

  2/21/2019

  "Geosaurus, Powered by Bayer" Will Support Start-Ups and Workforce Programs Focused on Geospatial Technology

• 

  Companies Announce Job Openings in the Wake of Expansions - Some Cuts Were Made, Too

  2/21/2019

  If you’re in the pharma or biotech industry and are looking for work, multiple companies have announced expansions of their employee pool over the past few days. BioSpace rounds up a few of the announcements.
• 

  Bayer, Janssen and BMS Unveil Promising Data for Prostate Cancer at ASCO GU

  2/15/2019

  As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.

• Bayer's investigational drug darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer

  2/14/2019

  First results from the Phase III ARAMIS trial with the investigational androgen receptor antagonist darolutamide were presented in an oral presentation at American Society of Clinical Oncology Genitourinary Cancers Symposium and simultaneously published in The New England Journal of Medicine

• Bayer donates $130,000 to 13 domestic violence shelters through new Grants Fur Families program

  2/13/2019

  Program enables domestic violence shelters to offer on-site pet care so women aren't forced to choose between staying in a dangerous situation and leaving their pet behind

• Bayer's Ray Kerins Elected Chairman of U.S. Chamber of Commerce's Global Innovation Policy Center

  2/7/2019

  Bayer U.S. announced today that Raymond F. Kerins, Jr., Senior Vice President of Corporate Affairs, is the new Chairman of the U.S. Chamber of Commerce's Global Innovation Policy Center (GIPC).

• 

  Takeda's Hemophilia A Drug: New Data and a $155 Million Patent Infringement Settlement

  2/6/2019

  Takeda Pharmaceutical released data from its Phase IIIb/IV clinical trial for Adynovate. On the same day, jurors in a Delaware federal court ordered Takeda’s Baxalta unit to pay $155.19 million to Bayer AG for infringing a patent for Adynovate.

• Bayer to Showcase New Data from its Growing Cancer Portfolio at 2019 ASCO GU Cancers Symposium

  2/5/2019

  First presentation of data from the pivotal Phase III ARAMIS trial with the investigational compound darolutamide in patients with non-metastatic castration-resistant prostate cancer

• Build a Foundation for Plentiful Potatoes

  1/10/2019

  Tempting tubers get their good looks and heavy weights from healthy roots.

• Bayer Statement on Updated Protocol for Postmarket Essure Study

  12/20/2018

  Safety and efficacy of Essure® have not changed

• HitGen and Bayer Enter DNA-Encoded Library Based Research Collaboration

  12/20/2018

  Program could lead to new crop protection solutions for farmers worldwide

• 

  When 2019 Rolls Around, Drug Companies Are Planning Price Hikes on Many Medicines

  12/20/2018

  An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.